Chantix to be Reviewed by FDA

by Kathy Jones on  December 13, 2012 at 8:34 PM Drug News
RSS Email Print This Page Comment
The US Food and Drug Administration has finally revealed that it will be reviewing Pfizer's anti-smoking drug, Chantix, nearly 18 months after first coming out with a warning that the drug could be associated with increased cardiovascular risk.
 Chantix to be Reviewed by FDA
Chantix to be Reviewed by FDA
Advertisement

The agency had first released the warning back in June 2011 after studies revealed that people who took the drug were more likely to suffer from cardiovascular diseases compared to people who did not take the drug. FDA had asked Pfizer to further evaluate the risk of the drug and the study observed around 4,190 Chantix users, of which 13 were found to have cardiovascular disease compared to 6 of the 2,812 people who were given placebo.

Advertisement
Pfizer admitted that Chantix could increase the risk of cardiovascular disease but the company spokesman, MacKay Jimeson said that the benefits of the drug outweighed the risks. "The benefits of quitting smoking are immediate and substantial. Chantix has been demonstrated to increase the likelihood of abstinence from smoking for as long as one year compared to treatment with placebo", Jimeson said.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive